About Avidity Biosciences

Avidity Biosciences is a pioneering biopharmaceutical company focused on transforming the treatment of rare diseases through the development of a novel class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™)[1][2]. The company’s mission centers on profoundly improving patients’ lives by overcoming one of the biggest challenges in RNA medicine: delivering therapeutic oligonucleotides to tissues and cell types beyond the liver, where traditional RNA drugs have struggled to reach[3]. By combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies, Avidity’s proprietary AOC platform enables targeted delivery of RNA therapeutics to previously inaccessible areas, directly addressing the genetic root causes of disease[1][3]. Founded with the vision to revolutionize RNA therapeutics, Avidity has rapidly established itself as a leader in the field. The company’s history is marked by scientific innovation, highlighted by its achievement as the first to demonstrate successful targeted delivery of RNA to muscle—a breakthrough that has opened new possibilities for treating rare muscle diseases[3]. Avidity’s clinical pipeline currently features three AOC programs targeting myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD), with additional programs in development for other neuromuscular and precision cardiology indications[4]. This expanding pipeline reflects Avidity’s commitment to addressing unmet medical needs across a broad spectrum of therapeutic areas, supported by both internal discovery efforts and strategic partnerships[4]. Avidity’s current status is that of a clinical-stage biotech company with a robust and growing portfolio, actively advancing multiple programs through clinical trials and early development[4]. The organization prides itself on building a diverse, agile, and collaborative team, guided by its BeAVID values (Agile, Visionary, Integrated, Diverse), to foster innovatio

Latest right now for Avidity Biosciences